Biocon

Biocon is Asia’s premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high-quality, life-saving biotherapeutics by making them affordable for patients across the world.

We have evolved from manufacturing pharmaceuticals like statins and immunosuppressants to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology, and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

Biocon was among the early movers in the industry to pursue a high-risk strategy of developing biosimilars for global markets. Through our ‘Made in India’ biosimilars business, we seek to pursue a humanitarian path that will provide affordable access to high-quality generic biologics to make a difference to diabetes, cancer and autoimmune diseases. We have succeeded in bringing the benefit of high-quality biosimilars to patients in India, other emerging market countries in Latin America, Africa, the Middle East, and Turkey, Asia-Pacific regions and also now in developed markets of US, EU, and Japan.

A combination of specialized talent, state-of-the-art research, and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global biopharmaceutical player.

Global Scale

Biocon has created large-scale fermentation capabilities to support the manufacturing of APIs like statins and immunosuppressants. We also built one of India’s largest bio-manufacturing facilities for insulins, monoclonal antibodies, and devices. We continue to invest in expanding our manufacturing capacities to address the growing market need.

Biocon’s insulin manufacturing and R&D facility set up in Malaysia with an investment of USD 300 million is the largest integrated insulins facility in Asia. This is the largest foreign investment in biotechnology in Malaysia and respects our commitment to serving patients in different parts of the world.